Lupin Launches Sevelamer Hydrochloride Tablets in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Sevelamer Hydrochloride Tablets, 800 mg, having received an approval from the United States Food and Drug Administration (FDA). The product will be manufactured at Lupin's facility in Nagpur, India.

Sevelamer Hydrochloride Tablets, 800 mg is a generic equivalent of Renagele Tablets, 800 mg of Genzyme Corporation.

Sevelamer Hydrochloride Tablets, 800 mg (RLD: Renagel®) had estimated annual sales of USO 75 million in the U.S. (IQVIA MAT December 2021).

Shares of Lupin Limited was last trading in BSE at Rs. 745.70 as compared to the previous close of Rs. 742.25. The total number of shares traded during the day was 91075 in over 3496 trades.

The stock hit an intraday high of Rs. 748.65 and intraday low of 729.05. The net turnover during the day was Rs. 67182865.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 SevelamerHydrochlorideTablets Approval USFDA